Clinical Trial – Emicizumab – Hemophilia A

Genentech, Inc. is running a clinical trial to test a drug called Emicizumab to treat hemophilia A. This Phase IV, multicenter study will evaluate whether participants with Hemophilia A and inhibitors receiving emicizumab prophylaxis can safely undergo minor surgical procedures without prophylactic bypassing agents (BPA).

The drug is Emicizumab.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Actual Study Start Date : April 30, 2018
Estimated Primary Completion Date : June 28, 2019
Estimated Study Completion Date : June 28, 2019


Contact: Reference Study ID: ML39791 888-662-6728 (U.S. Only)

NCT Number

NCT number: NCT03361137

For enrollment please visit

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.